# name
Hepatitis B and A vaccination in HIV-infected adults: A review

# metadata.dc.description.abstract[].value
Hepatitis B and A account for considerable morbidity and
                mortality worldwide. Immunization is the most effective means of
                preventing hepatitis B and A. However, the immune response to
                both hepatitis vaccines seems to be reduced in HIV-infected
                subjects. The aim of this review was to analyze the
                immunogenicity, safety, long-term protection and current
                recommendations of hepatitis B and A vaccination among
                HIV-infected adults. The factors most frequently associated with
                a deficient level of anti-HBs or IgG anti-HAV after vaccination
                are those related to immunosuppression (CD4 level and HIV RNA
                viral load) and to the frequency of administration and/or the
                amount of antigenic load per dose. The duration of the response
                to both HBV and HAV vaccines is associated with suppression of
                the viral load at vaccination and, in the case of HBV
                vaccination, with a higher level of antibodies after
                vaccination. In terms of safety, there is no evidence of more,
                or different, adverse effects compared with HIV-free
                individuals. Despite literature-based advice on the
                administration of alternative schedules, revaccination after the
                failure of primary vaccination, and the need for periodic
                re-evaluation of antibody levels, few firm recommendations are
                found in the leading guidelines.

# metadata.dc.relation.ispartof[].value
Human Vaccines & Immunotherapeutics, 2015, vol. 11, num. 11, p. 2582-2598

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Hepatitis B and A vaccination in HIV-infected adults: A review